A Study to Compare S-217622 With Placebo in Non-Hospitalized High-Risk Participants With COVID-19
Status:
Not yet recruiting
Trial end date:
2023-08-17
Target enrollment:
Participant gender:
Summary
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among
participants who are in the subpopulation of participants who were not expected to receive
standard-of-care COVID-19 Group A therapy (defined as monoclonal antibody [mAb] treatment or
outpatient intravenous [IV] remdesivir).
Phase:
Phase 3
Details
Lead Sponsor:
Shionogi
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)